acquired
Stage
About
KalVista Pharmaceuticals develops orally-delivered small molecule medicines primarily focused on the treatment of hereditary angioedema (HAE). They innovate in treatments aiming to improve disease management and patient outcomes.
Explore KalVista's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.